Clinical Trials · NCT05486065
A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 245
- Start date
- Aug 2022
- Locations
- 130 sites, 5 countries
- Primary endpoint
- Change in Glycated Haemoglobin (HbA1c)